78 results
Page 4 of 4
F-1/A
cxx5p jrij166e7fxh9n
19 Mar 20
Registration statement (foreign) (amended)
12:21pm
F-1
3rkb 0xruw8j3a958k6
31 Jan 20
Registration statement (foreign)
12:00am
6-K
EX-99.1
ig8873qdb
11 Dec 19
Annual and Special General Meeting of Shareholders
4:38pm
424B5
kqt9n8k5c00vp xb
5 Dec 19
Prospectus supplement for primary offering
5:29pm
6-K
EX-99.2
8tag0xrib7piu 7qo
7 Nov 19
Therapix Biosciences and Destiny Biosciences Global Corp. Mutually Decide to Discontinue Negotiations on Planned Merger
5:22pm
F-3/A
o1rq2drfucpr
29 Aug 19
Shelf registration (foreign) (amended)
4:49pm
F-3
6kz4bd4hesbytn
22 Aug 19
Shelf registration (foreign)
5:25pm
6-K
EX-99.1
5wv2tqwd x5
31 Jul 19
Therapix Biosciences Announces Canadian Product License Issuance for TheraPEA (CannAmide™), a Non-Opiate Based Pain Management Supplement
4:03pm
424B5
rrjq vf6nd
1 Apr 19
Prospectus supplement for primary offering
6:57am
6-K
EX-99.1
b1yxzb tlp0ma6cohas
19 Mar 19
Therapix Biosciences Appoints Ambassador Ron Prosor as Executive Advisor
8:04am
6-K
EX-99.1
q8qyvt1yj09u2vx51yv6
17 Jan 19
Annual General Meeting of Shareholders
4:05pm
6-K
EX-99.1
viytpg2fd1jc
28 Nov 18
Management’s Discussion and Analysis of Financial Condition and Results of Operations
6:27am
424B2
tycg 1nzy
9 Aug 18
Prospectus for primary offering
11:19am
F-3/A
ijodqg14e
17 Jul 18
Shelf registration (foreign) (amended)
1:29pm
F-3
qk2wy17
20 Jun 18
Shelf registration (foreign)
2:38pm
6-K
lvysi98b4r69
17 May 18
Report of Foreign Private Issuer
7:44am
20-F
2fv 0fyafgp
1 May 17
Annual report (foreign)
12:00am